Julie Kim
Metro Region: Boston
Member Since: 2023
She joined Takeda in 2019 through the acquisition of Shire, where she held several diverse roles with increasing responsibility. As part of Takeda, she became the President of the Plasma-Derived Therapies Business Unit, the position she occupied until April of 2022, when she became President of the U.S. Business Unit and U.S. Country Head.
Julie has 30 years of experience in health care, with leadership positions at global, regional, country and functional levels. In the biopharmaceutical industry, her experiences have spanned a variety of therapeutic areas, international market access, country and regional general management, marketing and emerging market development.
Julie is known for strong, collaborative and inclusive leadership that enables Takeda to meet the needs of the people the company serves while driving innovations that will improve patients’ lives. Her global outlook, a result of having worked in many countries in Europe, Asia and Latin America, as well as having lived in the U.K., Switzerland and the U.S., have helped her create teams that are diverse in multiple dimensions to enable inclusive decision-making that keeps the patient at the center.
Julie serves on the boards of directors for PhRMA, an organization which represents the country’s leading innovative biopharmaceutical research companies, and Croda International, a company which leverages smart science to create high-performance ingredients and technologies that improve lives. She was named one of Boston’s 50 Most Influential Asian American Pacific Islanders in 2023, to The 2022 PharmaVoice 100 list and to Fierce Pharma’s list of 2020’s Fiercest Women in Life Sciences.
She earned an M.B.A. from the J. L. Kellogg Graduate School of Management at Northwestern University and a B.A. in economics from Dartmouth College. She resides with her family in the Boston area.